Abstract
Fibromyalgia still represents an enigma to modern medicine and the aetiopathogenesis is far from explored. The management of patients with fibromyalgia is thus mostly based on empirical research, and only a few controlled studies have been performed. Basic drug therapy rests on the administration of amitriptyline and conventional analgesics. Such therapy should be initiated only after careful patient information and delineation of therapeutic goals are provided. Any drug therapy should be administered in combination with physical treatment and cognitive behavioural therapy. Because of the appearing contours of pathogenic mechanisms, hopefully a number of new drugs will be available to the patients with this complex pain syndrome in the near future.
Similar content being viewed by others
References
Wolfe F. The clinical syndrome of fibrositis. Am J Med 1986 Sep 29; 81 Suppl. 3A: 7–14
Yunus M, Masi A, Aldag J. A controlled study of primary fibromyalgia syndrome: clinical features and association with other functional syndromes. JRheumatol 1989 Feb; 16 Suppl. 19: 62–71
Wolfe F, Smythe H, Yunus M, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990 Feb; 33(2): 160–72
Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995 Jan; 38(1): 19–28
Raspe H, Baumgartner C. The epidemiology of the fibromyalgia syndrome (FMS) in German town [abstract]. Scand J Rheumatol 1992; Suppl. 94: S8
Lydell C. The prevalence of fibromyalgia in a south African community [abstract]. Scand J Rheumatol 1992; Suppl. 94: S8
Buskila D, Press J, Klein M, et al. Assessment of nonarticular tenderness and prevalence of fibromyalgia in children. J Rheumatol 1993 Feb; 20(2): 368–70
Forseth KØ, Gran JT. The prevalence of fibromyalgia among women aged 20–49 years in Arendal, Norway. Scand J Rheumatol 1992; 21(2): 74–8
Bengtsson A, Henriksson K, Jorfeldt L, et al. Primary fibromyalgia: a clinical and laboratory study of 55 patients. Scand J Rheumatol 1986; 15(3): 340–7
Cathey MA, Wolfe F, Kleinheksel SM, et al. Functional ability and work status in patients with fibromyalgia. Arthritis Care Res 1988; 1:85–98
Turk D, Rudy T, Stieg R. The disability determination dilemma: toward a multiaxial solution. Pain 1988 Sep; 34(3): 217–29
McCain G, Cameron R, Kennedy J. The problem of longterm disability payments and litigation in primary fibromyalgia: the Canadian perspective. J Rheumatol 1989 Nov; 16 Suppl. 19: 174–6
Henriksson CM. Longterm effects of fibromyalgia on everyday life: a study of 56 patients. Scand J Rheumatol 1994; 23(1): 36–41
Wolfe F, Aarflot T, Bruusgaard D, et al. Fibromyalgia and disability. Report of the Moss International Working Group on medico-legal aspects of chronic widespread pain complaints and fibromyalgia. Scand J Rheumatol 1995; 24(2): 112–8
Gjesdahl S, Kristiansen AM. The rise and possible fall of the Norwegian fibromyalgia epidemic: what does insurance statistics show [in Norwegian]. Tidsskr Nor Lægeforen 1997; 117: 249–53
Forseth KØ, Gran JT, Husby G. A population study of the incidence of fibromyalgia among women aged 26–55 yr. Br J Rheumatol 1997 Dec; 36(12): 1318–23
Felson D. Epidemiologic research in fibromyalgia. J Rheumatol 1989 Nov; 16 Suppl. 19:7–11
Forslind K, Fredriksson E, Nived O. Does primary fibromyalgia exist? Br J Rheumatol 1990 Oct; 29(5): 368–70
Brückle W, Lautenschläger J, Müller W. The course and topography of pain in fibromyalgia. EULAR Bulletin 1992; 1:12–8
Nørregaard J, Bülow PM, Prescott E, et al. A four-year follow-up study in fibromyalgia: relationship to chronic fatigue syndrome. Scand J Rheumatol 1993; 22(1): 35–8
Ledingham J, Doherty S, Doherty M. Primary fibromyalgia syndrome: an outcome study. Br J Rheumatol 1993 Feb; 32(2): 139–42
Bengtsson A, Bäckman E, Lindblom B, et al. Term follow-up of fibromyalgia patients: clinical symptoms, muscular function, laboratory tests: an eight year comparison study. J Musculoskel Pain 1994; 2: 67–79
Granges G, Zilko P, Littlejohn G. Fibromyalgia syndrome: assessment of the severity of the condition 2 years after diagnosis. J Rheumatol 1994 Mar; 21(3): 523–9
Buskila D, Neumann L, Hershman E, et al. Fibromyalgia syndrome in children: an outcome study. J Rheumatol 1995 Mar; 22(3): 525–8
Mikkelson M. One year outcome of preadolescents with fibromyalgia. J Rheumatol 1999; 26: 674–82
Forseth KØ, Førre Ø, Gran JT. A 5.5 years prospective study of self-reported musculoskeletal pain and of fibromyalgia in a female population; significance and natural history. Clin Rheumatol 1999; 18(2): 114–21
Pellegrino M, Waylonis G, Sommer A. Familial occurrence of primary fibromyalgia. Arch Phys Med Rehabil 1989; 70: 61–3
Buskila D, Neumann L, Hazanov I, et al. Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum 1996 Dec; 26(3): 605–11
Yunus M, Khan M, Rawlings K, et al. Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999 Feb; 26(2): 408–12
Bondy B, Spaeth M, Offenbaecher M, et al. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 1999 Oct; 6(5): 433–9
Hudson J, Pope H. Fibromyalgia and psychopathology: is fibromyalgia a form of ’affective spectrum disorder’? J Rheumatol 1989 Nov; 16 Suppl. 19: 15–22
Bennett R. Confounding features of the fibromyalgia syndrome: a current perspective of differential diagnosis. J Rheumatol 1989 Nov; 16 Suppl. 19: 58–61
Bennett R. Physical fitness and muscle metabolism in the fibromyalgia syndrome: an overview. J Rheumatol 1989 Nov; 16 Suppl. 19: 28–9
Pongratz DE. Zur Myopathologie der generalisierten ten-domyopathie. In: Müller W, editor. Generalisierte ten-domyopathie. Darmstadt: Steinkopff, 1991: 145–52
Bengtsson A, Henriksson K. The muscle in fibromyalgia: a review of Swedish studies. J Rheumatol 1989 Nov; 16 Suppl. 19: 144–9
Drewes A, Andreasen A, Schrøder HD, et al. Pathology of skeletal muscle in fibromyalgia: a histo-immuno-chemical and ultrastructural study. Br J Rheumatol 1993 Jun; 32(6): 479–83
Smythe H. ‘Fibrositis’ as a disorder of pain modulation. Clin Rheum Dis 1979; 5: 823–32
Smythe H. Tender points: evolution of concepts of the fibrositis/fibromyalgia syndrome. Am J Med 1986 Sep; 81 Suppl. 3A: 2–6
Smythe H. Fibrositis syndrome: a historical perspective. J Rheumatol 1989 Nov; 16 Suppl 19: 2–6
Yunus M. Towards a model of pathophysiology of fibromyalgia: abberant central pain mechanisms with peripheral modulation. J Rheumatol 1992 Jun; 19(6): 846–9
Henriksson K, Mense S. Pain a nociception in fibromyalgia: clinical and neurobio-logical considerations on aetiology and pathogenesis. Pain Rev 1994; 1: 245–60
Russell IJ. Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci 1998 Jun; 315(6): 377–85
Vasrøy H, Helle R, Førre ø, et al. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988 Jan; 32(1): 21–6
Russell IJ. Pathogenesis of fibromyalgia: the neurohormonal hypothesis. J Musculoskel Pain 1994; 2: 73–86
Bradley LA, Alberts KR, Alarcon GS. Abnormal brain regional cerebral flow (rCBF) and cerebrspinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM) [abstract]. Arthritis Rheum 1996; 39 Suppl. 9: S212
Russell IJ. Neurochemical pathogenesis of fibromyalgia syndrome. J Musculoskel Pain 1996; 4: 61–92
Larson AA, Giovengo SL, Russell IJ, et al. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000 Aug; 87(2): 201–11
Willis WD. The pain system: the neural basis of nociceptive transmission in the mammalian nervous system. Basel: Karger, 1985
Moldofsky H. Sleep and musculoskeletal pain. Am J Med 1986; 81 Suppl 3A: 85–9
Moldofsky H. Sleep and fibrosis syndrome. Rheum Dis Clin North Am 1989 Feb; 15(1): 91–100
Neeck G. Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients. Scand J Rheumatol 2000; 29 Suppl. 113: 8–12
Wolfe F, Cathey M, Kleinheksel S. Fibrositis (fibromyalgia) in rheumatoid arthritis. J Rheumatol 1984 Dec; 11(6): 814–8
Bonafede RP, Downey C, Bennett R. An association of fibromyalgia with primary Sjögren’s Syndrome: a prospective study of 72 patients. J Rheumatol 1995 Jan; 22(1): 133–6
Wallace D, Romano T. Prevalence of fibromyalgia in systemic lupus erythematosus patients: comment on the article by Middleton, et al. Arthritis Rheum 1995 Jun; 38(6): 872
Cimmino M, Parisi M, Moggiana G, et al. The association between fibromyalgia and carpal tunnel syndrome in the population [abstract]. Ann Rheum Dis 1996 Oct; 55(10): 780
Bennett RM, Clark SR, Goldberg L, et al. Aerobics fitness in patients with fibrositis. A controlled study of respiratory gaz exchange nd 133 xenon clearance from exercising muscle. Arthritis Rheum 1989 Apr; 32(4): 454–60
Clark S, Burkhardt CS, Campbell S. Fitness characteristics and perceived exertion in women with fibromyalgia. J Musculoskel Pain 1993; 1: 193–7
McCain G, Bell D, Mai F, et al. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum 1988 Sep; 31(9): 1135–41
Wigers S, Stiles T, Vogel PA. Effects of aerobic exercise versus stress management treatment in fibromyalgia: a 4.5 year prospective study. Scand J Rheumatol 1996; 25(2): 77–86
Martin L, Nutting A, Macintosh BR, et al. An exercise program in the treatment of fibromyalgia. J Rheumatol 1996 Jun; 23(6): 1050–3
Nichols D, Glenn DS. Effects of aerobic exercise on pain perception, affect, and level of disability in individuals with fibromyalgia. Phys Ther 1994 Apr; 74(4): 327–32
Verstappen FTJ, van Santen-Hoefft HMS, Bolwijn PH, et al. Effects of a group activity program for fibromyalgia patients on physical fitness and well being. J Musculoskel Pain 1997; 5: 17–28
Mengshoel AM, Førre Ø. Physical fitness training in patients with fibromyalgia. J Musculoskel Pain 1993; 1: 267–72
Wigers SH. Fibromyalgia outcome: the predictive values of symptom duration, physical activity, disability pension, and critical life events: a 4.5 year study. J Psychosom Res 1996 Sep; 41(3): 235–43
Minor MA, Sanford MK. The role of physical therapy and physical modalities in pain management. Rheum Dis Clin North Am 1999 Feb; 25(1): 233–48
Melzack R, Wall PD. Pain mechanism: a new theory. Science 1965 Nov; 150(699): 971–9
Justins DM. Management strategies for chronic pain. Ann Rheum Dis 1996 Sep; 55(9): 588–96
Johnson MI, Ashton CH, Thompson JW. An in-depth study of long-term users of transcutaneous electrical nerve stimulation (TENS): implications for clinical use of TENS. Pain 1991 Mar; 44(3): 221–9
Berman B, Ezzo J, Hadhazy V, et al. Is acupuncture effective in the treatment of fibromyalgia? J Fam Pract 1999 Mar; 48(3): 213–8
Deluze C, Bosia 1, Zirbs A, et al. Electroacupuncture in fibromyalgia: results of a controlled trial. BMJ 1992 Nov 21; 305(6864): 1249–52
Ferraccioli G, Ghirelli L, Scita F, et al. EMG-biofeedback training in fibromyalgia syndrome. J Rheumatol 1987 Aug; 14(4): 820–5
Buckelew SP, Conway R, Parker J, et al. Biofeedback/relaxation training and exercise interventions for fibromyalgia: a prospective trial. Arthritis Care Res 1998 Jun; 11(3): 196–209
Bradley L. Cognitive-behavioral therapy for primary fibromyalgia. J Rheumatol 1989; 16 Suppl. 19: 131–6
Morley S, Eccleston C, Wiliams A. Systematic review and meta-analyses of randomized controlled trials of cognitive behaviour therapy and behavioural therapy for chronic pain in adults, excluding headache. Pain 1999 Mar; 80(1–2): 1–13
Sandström MJ, Keefe FJ. Self-management of fibromyalgia: the role of formal coping skills training anf physical exercise training programs. Arthritis Care Res 1998 Dec; 11(6): 432–47
Lautenschläger J. Present state of medication therapy in fibromyalgia syndrome. Scand J Rheumatol 2000; 29 Suppl. 113: 32–6
Goldenberg D, Felson D, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986 Nov; 29(11): 1371–7
Yunus M, Masi A, Aldag J. Short term effects of ibuprofen in primary fibromyalgia syndrome: a double-blind, placebo controlled trial. J Rheumatol 1989 Apr; 16(4): 527–32
Russell IJ, Fletcher E, Michalek JE, et al. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: a double-blind, placebo-controlled study. Arthritis Rheum 1991 May; 34(5): 552–60
Quijada-Carrera J, Valenzuela-Castano A, Povedano-Gomez J. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain 1996 May–Jun; 65(2-3): 221–5
Værøy H, Abrahamsen A, Førre Ø, et al. Treatment of fibromyalgia (Fibrositis syndrome): a parallel double-blind trial with carioprodol, paracetamol and caffeïne (Somadril comp) versus placebo. Clin Rheumatol 1989 Jun; 8(2): 245–50
Wolfe F, Zhao S, Lane N. Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000 Feb; 43(2): 378–85
Biasi G, Manca S, Manganelli S, et al. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 1998; 18(1): 13–9
Russell IJ. Kamin M, Bennett RM, et al. Efficacy of tramadol in treatment of pain in fibromyalgia. Clin Rheumatol 2000; 6(5): 250–7
Bennett RM, Gatter RA, Campbell SM, et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum1988 Dec; 31(12): 1535–42
Quimby LG, Gratwiick GM, Whitney CD, et al. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol 1989 Nov; 16 Suppl. 19: 140–3
Reynolds WJ, Moldofsky H, Saskin P, et al. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 1991 Mar; 18: 452–4
Carette S, Bell M, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. Arthritis Rheum 1994 Jan; 37(1): 32–40
Drewes A, Andreasen A, Jennum P, et al. Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol 1991; 20(4): 288–93
Grönblad M, Nykänen J, Konttinen Y, et al. Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients: a double-blind randomized trial. Clin Rheumatol 1993 Jun; 12(2): 186–91
Moldofsky H, Lue F, Mously C, et al. The effect of zolpidem in patients with FM: a dose ranging, double-blind, placebo controlled, modified crossover study. J Rheumatol 1996 Mar; 23(3): 529–33
Clark S, Tindall E, Bennett R. A double crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 1985 Oct; 12(5): 980–3
Hannonen P, Malminiemi K, Yli-Kerttula U, et al. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998 Dec; 37(12): 1279–86
Wolfe F, Cathey M, Hawley D. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994; 23(5): 255–9
Nörregaard J, Volkmann H, Danneskiöld-Samsöe B. Arandomized controlled trial of citalopram inn the treatment of fibromyalgia. Pain 1995 Jun; 61(3): 445–9
Cantini F, Bellandi F, Niccolo L, et al. Fluoxetine combined with cyclobenzaprine in the treatment of fibromyalgia [in Italian]. Minerva Med 1994 Mar; 85(3): 97–100
Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996 Nov; 39(11): 1852–9
Andenberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Eur J Pain 2000; 4(1): 27–35
Celiker R. Comparison of amitriptyline and sertraline in the treatment of fibromyalgia [abstract]. Arthrit Rheum 2000 Sep; 43 Suppl. 9: S332
Carette S, McCain G, Bell D, et al. Evaluation of amitriptyline in primary fibrositis a double-blind, placebo-controlled study. Arthritis Rheum 1986 May; 29(5): 655–9
Scudds R, McCain G, Rollman G, et al. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol 1989 Nov; 16 Suppl. 19: 98–103
Jaeschke R, Adachi J, Guyatt G, et al. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol 1991 Mar; 18(3): 447–51
Hong CZ. Lidocaine injection versus dry needling to myofascial trigger point. Am J Phys Med Rehabil 1994 Jul–Aug; 73(4): 256–63
Hong CZ, Hsueh TC. Difference in pain relief after triggerpoint injections in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil 1996 Nov; 77(11): 1161–6
Borg-Stein J, Stein J. Triggerpoints and tenderpoints: one and the same? Does injection treatment help? Rheum Dis Clin North Am 1996 May; 22(2): 305–22
Lofland JH, Szarlej D, Buttaro T, et al. Cyclobenzaprine hydrochloride is a commonly prescribed centrally acting muscle relaxant, which is structurally similar to tricyclic antidepressants (TCAs) and differs from amitriptyline by only one double bond. Clin J Pain 2001 Mar; 17(1): 103–4
Travell JG, Simmons DG. Myofascial pain and dysfunction. The triggerpoint manual. Baltimore: Williams and Wilkins, 1983
Hansen H. Treatment of chronic pain with antiepileptic drugs: a new era. South Med J 1999 Jul; 92(7): 642–9
Besette L, Carette S, Fossel A, et al. A randomized, double-blind, placebo-controlled crossover trial of subcutaneous salmon calcitonin in the treatment of patients with fibromyalgia. Scand J Rheumatol 1998 (2); 27: 112–26
Jacobsen S, Danneskiold-Samsøe B, Bach Andersen R. Oral S-adenosylmethionine in primary fibromyalgia: double-blind clinical evaluation. Scand J Rheumatol 1991; 20(4): 294–302
Volkmann H, Nørregaard J, Jacobsen S, et al. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. Scand J Rheumatol 1997; 26(3): 206–11
Caruso I, Puttini PS, Cazzola M, et al. Double-blind study of %-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990 May; 18(3): 201–9
Puttini PS, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J Int Med Res 1992 Apr; 20(2): 182–9
Relja M. Treatment of tension-type headache by local injection of botulinum toxin. Eur J Neurol 1997; 4 Suppl 2: S71–3
McCarty DJ, Csuka M, McCarthy G, et al. Treatment of pain due to fibromyalgia with topical capsaicin: a pilot study. Semin Arthritis Rheum 1994; 23(6): Suppl. 3: 41–7
Scharf M, Hauck M, Stover R, et al. Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia: preliminary report. J Rheumatol 1998 Oct; 25(10): 1986–90
Bennett RM, Clark SC, Walczyk J. Arandomized, double-blind, placebo-controlled study of growth hormone in the treatment of patients with fibromyalgia. Am J Med 1998 Mar; 104(3): 227–31
McMahon S, Bennett DL, Priestley JV, et al. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med 1995 Aug; 1(8): 774–80
Holman Renton AJ. Safety and efficacy of the dopamine agonist, pramipexole, on pain score for refractory fibromyalgia [abstract]. Arthritis Rheum 2000 Sep; 43 Suppl. 9: S333
Abraham GE, Flechas JD. Management of fibromyalgia: rationale for the use of magnesium and malic acid. J Nutr Med 1992; 3: 49–59
Sørensen J, Bengtsson A, Backman E, et al. A pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 1995; 24(6): 360–5
Øye I, Rabben T, Fagerlund TH. Analgesic effect of ketamine in a patient with neuropathic pain [in Norwegian]. Tidsskr Nor Lægeforen 1996 Okt; 116(26): 3130–1
Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000 Apr; 85(3): 483–91
Haines D, Gaines S. N of 1 randomised controlled trials of oral ketamine in patients with chronic pain. Pain 1999 Nov; 83(2): 283–7
Clark SR, Bennett RM. Supplemental dextromethorphan in the treatment of fibromyalgia: a double-blind, placebo-controlled study of efficacy and side-effects [abstract]. Arthritis Rheum 2000 Sep; 43 Suppl. 9: S333
Höcherl K, Färber L, Ladenburger S, et al. Effect of tropisetron on circulating catecholamines and other putative biochemical markers in serum of patients with fibromyalgia. Scand J Rheumatol 2000; 29 Suppl. 113: 46–8
Färber L, Stratz T, Brückle W, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia — a highly selective and competitive 5-HT3 receptor antagonist. Scand J Rheumatol 2000; 29 Suppl. 113: 49–54
Haus U, Boglarka V, Stratz T, et al. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol 2000; 29 Suppl. 113: 55–8
Müller W, Stratz T. Results of the intravenous administration of tropisetron in fibromyalgia patients. Scand J Rheumatol 2000; 29 Suppl. 113:59–62
Birdsall TC. 5-hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev 1998 Aug; 3(4): 271–80
Brin MF. Botulinum toxin: new and expanded indications. Eur J Neurol 1997; 4 Suppl. 2: S59–65
Holzer P. Capsaicin: Cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Am Soc Pharmacol Exp Ther 1991;43: 143–201
Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999 Jul; 26(7): 1564–9
Hewitt DJ. The Use of NMDA-receptor Antagonists in the treatment of Chronic Pain. Clin J Pain 2000 Jun; 16 Suppl. 2: S73–9
Max MB, Byas-Smith MG, Gracely RH, et al. Intravenous infusoion of the NMDA antagonist, ketamine, in chronic post-traumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Clin Neuropharmacol 1995 Aug; 18(4): 360–8
Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997 May; 48(5): 1212–8
Eide K, Stubhaug A, øye I, et al. Continuous subcutaneous administration of the N-methyl-D-aspartatic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 1995 May; 61(2): 221–8
Nikolajsen L, Hansen CL, Nielsen J, et al. The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input. Pain 1996 Sep; 67(1): 69–77
Felsby S, Nielsen J, Arendt-Nielsen L, et al. NMDA rceptor blockade in chronic nuropathic pain: a comparison of ketamine and magnesium chloride. Pain 1996 Feb; 64(2): 283–91
Eide K, Stubhaug A. Relief of glossopharyngeal neuralgia by ketamine-induced N-methyl-D-aspartate receptor blockade. Neurosurgery 1997; 41: 505–8
Pud D, Eisenberg E, Spitzer A, et al. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain 1998 Apr; 75(2–3): 349–54
Kinnman E, Nygards EB, Hansson P. Effects of dextromethorphan in clinical doses on capsaicin-induced ongoing pain and mechanical hypersensitivity. J Pain Symptom Manage 1997 Oct; 14(4): 195–201
McQuay HJ, Carroll D, Jadad AR, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design. Pain 1994 Oct; 59(1): 127–33
Mercadante S, Casuccio A, Genovese G. Ineffectiveness of dextromethorphan in cancer pain. J Pain Symptom Manage 1998 Nov; 16(5): 317–22
Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol 2000; 29 Suppl. 113: 37–45
GlaxoSmithKline. Press release. Available from URL: http://www.gsk.com/press_archive/mn_PR975485699.htm [Accessed 02 01 25]
Acknowledgements
No funding that were used to assist in the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Forseth, K.Ø., Gran, J.T. Management of Fibromyalgia. Drugs 62, 577–592 (2002). https://doi.org/10.2165/00003495-200262040-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200262040-00003